LIPODOX (DOXORUBICIN HCL PEGYLATED LIPOSOMAL)
- AIDS with kaposi's sarcoma
- Malignant neoplasm of the ovary
- Multiple myeloma
- Lipodox Iv
- Lipodox Intravenous Suspension
- Lipodox Intravenous Solution
- Lipodox 50 Iv
- Lipodox 50 Intravenous Suspension
- Lipodox 50 Intravenous Solution
- Doxorubicin, Pegylated Liposomal Intravenous Suspension
- Doxorubicin, Pegylated Liposomal Intravenous Solution
- Doxil Iv
- Doxil Intravenous Suspension
- Doxil Intravenous Solution
- By Indication
2 mg/mL intravenous suspension
- Dosage information is not available
2 mg/mL intravenous suspension
- Dosage information is not available
2 mg/mL intravenous suspension
- Dosage information is not available
2 mg/mL intravenous suspension
- Dosage information is not available
2 mg/mL intravenous suspension
- Dosage information is not available
2 mg/mL intravenous suspension
- Dosage information is not available
doxorubicin, pegylated liposomal 2 mg/mL intravenous suspension
- Dosage information is not available
doxorubicin, pegylated liposomal 2 mg/mL intravenous suspension
- Dosage information is not available
2 mg/mL intravenous suspension
- Dosage information is not available
2 mg/mL intravenous suspension
- Dosage information is not available
2 mg/mL intravenous suspension
- Dosage information is not available
AIDS with kaposi's sarcoma
- Infuse 20 mg/m2 over 60 minute(s) by intravenous route every 21 days
Malignant neoplasm of the ovary
- Infuse 50 mg/m2 over 60 minute(s) by intravenous route every 28 days
Multiple myeloma
- Infuse 30 mg/m2 over 60 minute(s) by intravenous route on day 4 of a 21 day cycle
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- natalizumab
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- typhoid vaccine
- Tysabri
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- abacavir-lamivudine-zidovudine
- ado-trastuzumab emtansine
- B3,azel,quer&tur-FA-B6-zn-copp
- clozapine
- Clozaril
- Combivir
- deferiprone
- Fazaclo
- Ferriprox
- glucosam-csa-mv-min AA-hrb 162
- Herceptin
- Kadcyla
- ketoconazole
- lamivudine-zidovudine
- mag oxide-D3-turmeric rt xt
- me-thfolate gluc-B12-herb #236
- milk prot-turm-pepper-pinea ex
- Nicazel Forte
- nut.tx, metab.dis, mv & min #4
- Proteolin
- Proteolin Ds
- Retrovir
- Rheumate
- stavudine
- trastuzumab
- Trizivir
- Ultra Inflamx Plus 360
- Versacloz
- Zerit
- zidovudine
Severe
Moderate
- Abraxane
- Digox
- digoxin
- Lanoxin
- Onxol
- paclitaxel
- paclitaxel-protein bound
- 30 day risk period post-myocardial infarction
- Cardiomyopathy
- Glucose-6-phosphate dehydrogenase (g6Pd) deficiency
- Heart failure
- Hemolytic anemia from PK and g6PD deficiencies
- Lactating mother
Contraindicated
- Anemia
- Atrioventricular block
- Bundle branch block
- Cardiac arrhythmia
- Disease of liver
- Myocarditis
- Neutropenic disorder
- Palmar-plantar erythrodysesthesia
- Pregnancy
- Severe infection
- Thrombocytopenic disorder
Severe
Moderate
- Asymptomatic left ventricular dysfunction
LIPODOX (DOXORUBICIN HCL PEGYLATED LIPOSOMAL)
- AIDS with kaposi's sarcoma
- Malignant neoplasm of the ovary
- Multiple myeloma
- Anemia
- Chills
- Drug fever
- Dyspnea
- Facial edema
- General weakness
- Headache disorder
- Hypotension
- Neutropenic disorder
- Palmar-plantar erythrodysesthesia
- Skin rash
- Stomatitis
- Thrombocytopenic disorder
- Alopecia
- Anorexia
- Constipation
- Diarrhea
- Fatigue
- Leukopenia
- Nausea
- Vomiting
More Frequent
Severe
Less Severe
- Bullous dermatitis
- Cardiac arrest
- Cardiac arrhythmia
- Cardiotoxicity
- Chronic heart failure
- Deep venous thrombosis
- Dehydration
- Erythema
- Exfoliative dermatitis
- Fungal infection of skin
- Furunculosis
- Herpes simplex infection
- Herpes zoster
- Hyperbilirubinemia
- Hypercalcemia
- Hypokalemia
- Hyponatremia
- Ileus
- Injection site sequelae
- Maculopapular rash
- Pneumonia
- Postirradiation erythema
- Pruritus of skin
- Rectal bleeding
- Skin scaling of feet
- Skin scaling of hands
- Skin swelling
- Tachycardia
- Throat constriction
- Acne vulgaris
- Back pain
- Chest tightness
- Conjunctivitis
- Cough
- Depression
- Dizziness
- Drowsy
- Dry eye
- Dry skin
- Dyschromia
- Dysgeusia
- Dysphagia
- Ecchymosis
- Epistaxis
- Flushing
- Hematuria
- Pharyngitis
- Rhinitis
- Sinusitis
- Urinary tract infection
- Vasodilation of blood vessels
- Vulvovaginal candidiasis
- Weight loss
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute myeloid leukemia
- Anaphylaxis
- Diabetes mellitus
- Erythema multiforme
- Hyperglycemia
- Jaundice
- Leucoplakia of oral mucosa
- Malignant tumor of oral cavity
- Optic neuritis
- Pulmonary thromboembolism
- Severe bone marrow depression
- Squamous cell carcinoma of mouth
- Stevens-johnson syndrome
- Toxic epidermal necrolysis
Less Severe
- Dyspepsia
- Esophagitis
- Hypertension
- Lichenoid keratosis
- Muscle spasm
- Oral candidiasis
- Seizure disorder
- Thrombophlebitis
- Venous thrombosis
Contraindicated
None
Severe Precaution
Doxorubicin (Liposomal)
No safety and efficacy for liposomal formulation. Non-liposomal form risks: delayed cardiotoxicity and heart failure, prepubertal growth failure, secondary AML, or other malignancy
- 1 Day – 18 Years
- No safety and efficacy for liposomal formulation. Non-liposomal form risks: delayed cardiotoxicity and heart failure, prepubertal growth failure, secondary AML, or other malignancy
Management or Monitoring Precaution
None
Doxorubicin Hcl Liposome
- Severity Level:
D
- Additional Notes: Insuff human data; animal data sug dev tox.
Contraindicated
Doxorubicin
Risk of immune suppression, possibly carcinogenic.
General | Excretion Potential | Effect on Infant | Notes |
Drug should not be given to breast feeding mothers | Excreted | Not known; no or inclusive data | Risk of immune suppression, possibly carcinogenic. |
Precaution Exists
None
General | Excretion Potential | Effect on Infant | Notes |
None |
No Known Risk
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- Liposomal doxorubicin may cause heart problems, including possibly fatal heart failure. Heart problems may occur during liposomal doxorubicin therapy or months to years after receiving this medication. Your risk of developing heart problems depends on your dose, medical history (including previous heart disease, radiation therapy in the chest area), and previous use of this and other drugs (including daunorubicin and cyclophosphamide).<br /><br />Children are at higher risk and should be monitored later in life for delayed heart problems. See also Side Effects section. This medication may cause certain severe (rarely fatal) blood disorders (bone marrow suppression leading to low red blood cells/white blood cells /platelets).<br /><br />This can lower your body's ability to fight infection and stop bleeding. Tell your doctor right away if you develop any signs of infection (e.g., fever, chills, persistent sore throat), unusual tiredness, or easy bleeding/bruising. While this drug is first being given into your vein, this medication may cause severe (rarely fatal) reactions, including allergic reactions.<br /><br />Tell your doctor right away if you experience flushing, trouble breathing, swelling of the face, tightness in the chest/throat, chills, back pain, severe dizziness, or fast heartbeat. See also Side Effects section. Tell your doctor if you have liver problems because the dose may need to be decreased.<br /><br /> Your doctor will closely monitor you while you are being treated with this medication. Different types of this medication work in different ways. Do not switch types of this medication without your doctor's permission.
AIDS with kaposi's sarcoma | |
C46 | Kaposi's sarcoma |
C46.0 | Kaposi's sarcoma of skin |
C46.1 | Kaposi's sarcoma of soft tissue |
C46.2 | Kaposi's sarcoma of palate |
C46.3 | Kaposi's sarcoma of lymph nodes |
C46.4 | Kaposi's sarcoma of gastrointestinal sites |
C46.5 | Kaposi's sarcoma of lung |
C46.50 | Kaposi's sarcoma of unspecified lung |
C46.51 | Kaposi's sarcoma of right lung |
C46.52 | Kaposi's sarcoma of left lung |
C46.7 | Kaposi's sarcoma of other sites |
C46.9 | Kaposi's sarcoma, unspecified |
Malignant neoplasm of the ovary | |
C56 | Malignant neoplasm of ovary |
C56.1 | Malignant neoplasm of right ovary |
C56.2 | Malignant neoplasm of left ovary |
C56.9 | Malignant neoplasm of unspecified ovary |
Multiple myeloma | |
C90.0 | Multiple myeloma |
C90.00 | Multiple myeloma not having achieved remission |
C90.02 | Multiple myeloma in relapse |
0-9 | A-Z |
---|---|
C46 | Kaposi's sarcoma |
C46.0 | Kaposi's sarcoma of skin |
C46.1 | Kaposi's sarcoma of soft tissue |
C46.2 | Kaposi's sarcoma of palate |
C46.3 | Kaposi's sarcoma of lymph nodes |
C46.4 | Kaposi's sarcoma of gastrointestinal sites |
C46.5 | Kaposi's sarcoma of lung |
C46.50 | Kaposi's sarcoma of unspecified lung |
C46.51 | Kaposi's sarcoma of right lung |
C46.52 | Kaposi's sarcoma of left lung |
C46.7 | Kaposi's sarcoma of other sites |
C46.9 | Kaposi's sarcoma, unspecified |
C56 | Malignant neoplasm of ovary |
C56.1 | Malignant neoplasm of right ovary |
C56.2 | Malignant neoplasm of left ovary |
C56.9 | Malignant neoplasm of unspecified ovary |
C90.0 | Multiple myeloma |
C90.00 | Multiple myeloma not having achieved remission |
C90.02 | Multiple myeloma in relapse |